Under investigation by the prosecutor of Siena for fraud regarding the 2009 supply of the swine flu vaccine, and in the antitrust's crosshairs with Laccused of having cartel with Roche regarding the price of a drug (Avastin-Leucentis), Novartis he consoles himself with the sales figures that come from further afield. In fact, the Swiss pharmaceutical giant declared that it benefited from a 2% leap in revenues in the second quarter of 2014, which occurred mainly thanks to emerging markets: sales in China, Russia and other emerging markets would in fact have increased by 8%, while the revenues generated by the growth of products launched since 2009 or which have market exclusivity until 2018, increased by 18%. A result that comes just as – as reported by «The Wall Street Journal» – the company is preparing for a review of its organization and its areas of interest.
The Basel-based company, permanent member of Big Pharma, would be about to complete a series of operations announced earlier this year and focused on the area of generic drugs and eye care, and is selling its holdings in diagnostics and vision companies to competitors GlaxoSmithKline and Eli Lilly and Co. animal care. A series of deals valued at more than $25 billion that are expected to be completed in the first half of 2015.
July 17, 2014 – values
